1. Home
  2. RFL vs KZIA Comparison

RFL vs KZIA Comparison

Compare RFL & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

N/A

Current Price

$1.05

Market Cap

133.1M

Sector

Finance

ML Signal

N/A

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

N/A

Current Price

$6.53

Market Cap

125.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RFL
KZIA
Founded
2017
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
133.1M
125.6M
IPO Year
2017
2002

Fundamental Metrics

Financial Performance
Metric
RFL
KZIA
Price
$1.05
$6.53
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $28.76
AVG Volume (30 Days)
53.3K
★ 173.7K
Earning Date
12-10-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 44.23
N/A
EPS
N/A
★ N/A
Revenue
★ $917,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 43.96
N/A
52 Week Low
$0.99
$4.86
52 Week High
$3.96
$17.40

Technical Indicators

Market Signals
Indicator
RFL
KZIA
Relative Strength Index (RSI) 34.12 32.56
Support Level $0.99 $4.86
Resistance Level $1.38 $14.85
Average True Range (ATR) 0.11 0.66
MACD 0.02 -0.02
Stochastic Oscillator 12.88 14.94

Price Performance

Historical Comparison
RFL
KZIA

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: